FOLP1: Dihydropteroate synthase
Protein in Mycobacterium leprae (strain TN) that 2 drugs act on.
- Drugs that act on it: 2
- Approved: 2
- In phases 1 to 3: 0
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on FOLP1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) | Dapsone | Phase 2 / Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | Nov 5, 2026 |
| Telacebec in Adults With Multibacillary Leprosy (TEBULA Leprosy Trial) | Dapsone | Phase 2 | Not yet recruiting | Fondation Raoul Follereau | Nov 5, 2026 |
| Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients | Dapsone | Not applicable | Recruiting | South Valley University | Feb 11, 2025 |
| Dermatitis Herpetiformis Refractory to Gluten Free Diet | Dapsone | — | Enrolling by invitation | Tampere University Hospital | Aug 18, 2023 |
| A Randomized Multicenter Study for Isolated Skin Vasculitis | Dapsone | Phase 2 | Recruiting | University of Pennsylvania | Oct 20, 2016 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2362993, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets